Overview

PROPHYLAXIS OF GVH IN ELDERLY PATIENTS RECEIVING HAPLOIDENTICAL ALLOGENIC HEMATOPOIETIC STEM CELL TRASNPLANTATION USE OF A LOW DOSE ANTI-LYMPHOCYTIC SERUM

Status:
Not yet recruiting

Trial end date:
2026-03-31

Target enrollment:

Participant gender:

Summary

The aim of this trial is to evaluate the efficacy of GVH prophylaxis reinforced by low-dose Thymoglobulin administered at the end of aplasia after haploidentical allogeneic transplantation. Patients will receive a single infusion of Thymoglobulin at a dose of 1 mg/kg between 48h and 72h after emergence from aplasia, and will be followed for 12 months.

Phase:

Phase 2

Details

Lead Sponsor:

Institut Paoli-Calmettes

Collaborator:

Sanofi

Treatments:

Thymoglobulin